Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision...
ALIM nearly doubled in price in 6 trading days this month. After retracing 61.8% of this move, ALIM broke out of its' narrow channel flag with decent volume. If we see follow through ALIMs' first target is 8.29.
